QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
NASDAQ:BIOL

BIOLASE (BIOL) Stock Forecast, Price & News

$0.08
-0.01 (-10.96%)
(As of 06/5/2023 ET)
Compare
Today's Range
$0.07
▼
$0.09
50-Day Range
$0.08
▼
$0.39
52-Week Range
$0.07
▼
$5.94
Volume
11.07 million shs
Average Volume
2.38 million shs
Market Capitalization
$2.54 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.63
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

BIOLASE MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
6,827.3% Upside
$5.63 Price Target
Short Interest
Healthy
3.69% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.27mentions of BIOLASE in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.87 out of 5 stars

See Top Rated MarketRank™ Stocks Here

BIOL stock logo

About BIOLASE (NASDAQ:BIOL) Stock

BIOLASE, Inc. is a medical device company, which engages in the developing, manufacturing, marketing and sale of laser systems in dentistry and medicine. It operates through the Waterlase (all-tissue) systems, and Diode (soft-tissue) systems products. The Waterlase systems use a patented combination of water and laser energy to perform procedures using drills, scalpels, and other traditional dental instruments for cutting soft and hard tissue. The Diode systems perform soft tissue, pain therapy, and cosmetic procedures, including teeth whitening. The company was founded in 1987 and is headquartered in Lake Forest, CA.

Receive BIOL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BIOLASE and its competitors with MarketBeat's FREE daily newsletter.

BIOL Stock News Headlines

June 5, 2023 | finance.yahoo.com
BIOLASE ANNOUNCES DISTRIBUTION OF SERIES I PREFERRED STOCK TO HOLDERS OF ITS COMMON STOCK
June 5, 2023 | marketwatch.com
Biolase to Cut 20% of Workforce
June 5, 2023 | Behind the Markets (Ad)
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
June 5, 2023 | msn.com
BIOLASE to cut 20% of US workforce to achieve sales and profitability goals
June 3, 2023 | americanbankingnews.com
BIOLASE (NASDAQ:BIOL) Coverage Initiated at StockNews.com
June 1, 2023 | nasdaq.com
Lake Street Maintains Biolase (BIOL) Buy Recommendation
May 31, 2023 | americanbankingnews.com
BIOLASE (NASDAQ:BIOL) PT Lowered to $1.50 at Lake Street Capital
May 29, 2023 | americanbankingnews.com
Insider Buying: BIOLASE, Inc. (NASDAQ:BIOL) Major Shareholder Acquires $797,837.91 in Stock
June 5, 2023 | Behind the Markets (Ad)
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
May 26, 2023 | finance.yahoo.com
BIOLASE Inc. Announces Closing of $4.5 Million Underwritten Public Offering of Series H Convertible Redeemable Preferred Stock and Warrants
May 25, 2023 | americanbankingnews.com
BIOLASE (NASDAQ:BIOL) Research Coverage Started at StockNews.com
May 24, 2023 | marketwatch.com
Biolase Hits 52-Week Low of 7 Cents After Offering Prices
May 24, 2023 | benzinga.com
Biolase shares are trading lower after the company announced the pricing of a $4.5 million underwritten public offering.
May 24, 2023 | finance.yahoo.com
BIOLASE Inc. Announces Pricing of $4.5 Million Underwritten Public Offering of Series H Convertible Redeemable Preferred Stock and Warrants
May 17, 2023 | americanbankingnews.com
BIOLASE (NASDAQ:BIOL) Now Covered by Analysts at StockNews.com
May 13, 2023 | marketwatch.com
Global Electronic Caries Monitors (ECM) Market Size 2023-2031 Technological Innovations by Absolute Reports | with [119 Pages]
May 11, 2023 | finance.yahoo.com
BIOLASE MAINTAINS MOMENTUM AND REPORTS NINTH CONSECUTIVE QUARTER OF YEAR-OVER-YEAR GROWTH; REITERATES FULL YEAR GUIDANCE OF AT LEAST 25% REVENUE GROWTH AND PROFITABILITY FOR FULL YEAR 2023
May 10, 2023 | msn.com
Earnings Outlook For Biolase
May 10, 2023 | markets.businessinsider.com
Biolase earnings: here's what Wall Street expects
May 10, 2023 | americanbankingnews.com
StockNews.com Initiates Coverage on BIOLASE (NASDAQ:BIOL)
May 10, 2023 | marketwatch.com
Laser Medical Instrument Market Size, Business Segments, Innovative Strategies And Outlook by 2030| El.En., Lumenis, BIOLASE
May 9, 2023 | americanbankingnews.com
BIOLASE (BIOL) Scheduled to Post Quarterly Earnings on Thursday
May 4, 2023 | finance.yahoo.com
BIOLASE TO REPORT FIRST QUARTER 2023 RESULTS ON MAY 11, 2023
April 22, 2023 | marketwatch.com
Global Dental Products Market by [2023-2029] with Revenue Outsourcing
April 15, 2023 | americanbankingnews.com
Short Interest in BIOLASE, Inc. (NASDAQ:BIOL) Increases By 127.0%
April 9, 2023 | marketwatch.com
Dental Hand Instruments Market Facts and Figures By 2030
April 8, 2023 | marketwatch.com
Semiconductor Laser Therapeutic Equipment Market Demand by 2030
See More Headlines

BIOL Price History

BIOL Company Calendar

Last Earnings
3/28/2023
Today
6/05/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Dental equipment & supplies
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BIOL
Previous Symbol
NASDAQ:BLTI
CUSIP
N/A
CIK
811240
Web
www.biolase.com
Phone
(949) 361-1200
Fax
949-273-6677
Employees
158
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.63
High Stock Price Forecast
$14.00
Low Stock Price Forecast
$1.50
Forecasted Upside/Downside
+6,827.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($3.47)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-28,630,000.00
Net Margins
-60.92%
Pretax Margin
-60.73%
Return on Equity
-244.91%
Return on Assets
-68.35%

Debt

Debt-to-Equity Ratio
1.53
Current Ratio
1.68
Quick Ratio
0.75

Sales & Book Value

Annual Sales
$48.46 million
Price / Sales
0.05
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.63 per share
Price / Book
0.13

Miscellaneous

Outstanding Shares
31,300,000
Free Float
31,139,000
Market Cap
$2.54 million
Optionable
Not Optionable
Beta
1.37

Key Executives

  • John R. Beaver
    President, Chief Executive Officer & Director
  • Steven Sandor
    Chief Operating Officer
  • Jennifer Brighton
    Chief Financial Officer
  • Russell Morrow
    Chief Dental Officer
  • William E. Brown
    Vice President-Innovation & Business Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













BIOL Stock - Frequently Asked Questions

Should I buy or sell BIOLASE stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BIOLASE in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BIOL shares.
View BIOL analyst ratings or view top-rated stocks.

What is BIOLASE's stock price forecast for 2023?

2 Wall Street research analysts have issued twelve-month price targets for BIOLASE's shares. Their BIOL share price forecasts range from $1.50 to $14.00. On average, they anticipate the company's share price to reach $5.63 in the next year. This suggests a possible upside of 6,827.3% from the stock's current price.
View analysts price targets for BIOL or view top-rated stocks among Wall Street analysts.

How have BIOL shares performed in 2023?

BIOLASE's stock was trading at $0.65 on January 1st, 2023. Since then, BIOL stock has decreased by 87.5% and is now trading at $0.0812.
View the best growth stocks for 2023 here.

When is BIOLASE's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our BIOL earnings forecast.

How were BIOLASE's earnings last quarter?

BIOLASE, Inc. (NASDAQ:BIOL) announced its earnings results on Tuesday, March, 28th. The medical technology company reported ($1.28) earnings per share (EPS) for the quarter. The medical technology company earned $14.05 million during the quarter. BIOLASE had a negative trailing twelve-month return on equity of 244.91% and a negative net margin of 60.92%.

When did BIOLASE's stock split?

BIOLASE's stock reverse split on the morning of Friday, April 29th 2022. The 1-25 reverse split was announced on Friday, April 29th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 29th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What guidance has BIOLASE issued on next quarter's earnings?

BIOLASE issued an update on its FY 2023 earnings guidance on Friday, May, 26th. The company provided EPS guidance of for the period. The company issued revenue guidance of $60.58M-, compared to the consensus revenue estimate of $59.91 million.

What is John R. Beaver's approval rating as BIOLASE's CEO?

4 employees have rated BIOLASE Chief Executive Officer John R. Beaver on Glassdoor.com. John R. Beaver has an approval rating of 13% among the company's employees. This puts John R. Beaver in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies. 35.0% of employees surveyed would recommend working at BIOLASE to a friend.

What other stocks do shareholders of BIOLASE own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BIOLASE investors own include Himax Technologies (HIMX), Accelerate Diagnostics (AXDX), Biocept (BIOC), Magnachip Semiconductor (MX), Fluidigm (FLDM), Matinas BioPharma (MTNB), MicroVision (MVIS), Acasti Pharma (ACST), Bionano Genomics (BNGO) and Genius Brands International (GNUS).

What is BIOLASE's stock symbol?

BIOLASE trades on the NASDAQ under the ticker symbol "BIOL."

Who are BIOLASE's major shareholders?

BIOLASE's stock is owned by many different retail and institutional investors. Top institutional shareholders include Perkins Capital Management Inc. (10.34%) and Renaissance Technologies LLC (0.53%). Insiders that own company stock include Education Foundation Schuler, John R Beaver, John R Beaver, Jonathan T Md Lord and Larry N Feinberg.
View institutional ownership trends.

How do I buy shares of BIOLASE?

Shares of BIOL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BIOLASE's stock price today?

One share of BIOL stock can currently be purchased for approximately $0.08.

How much money does BIOLASE make?

BIOLASE (NASDAQ:BIOL) has a market capitalization of $2.54 million and generates $48.46 million in revenue each year. The medical technology company earns $-28,630,000.00 in net income (profit) each year or ($3.47) on an earnings per share basis.

How many employees does BIOLASE have?

The company employs 158 workers across the globe.

How can I contact BIOLASE?

BIOLASE's mailing address is 27042 Towne Center Drive Suite 270, Lake Forest CA, 92610. The official website for the company is www.biolase.com. The medical technology company can be reached via phone at (949) 361-1200, via email at rcaron@dresnerallencaron.com, or via fax at 949-273-6677.

This page (NASDAQ:BIOL) was last updated on 6/5/2023 by MarketBeat.com Staff

My Account -